本帖最后由 老马 于 2013-3-13 13:43 编辑
1 j5 b3 a0 i- e2 P; }" |3 P6 \% p2 }5 z2 R8 h
健择（吉西他滨）+顺铂+阿瓦斯汀
/ N4 z/ b5 I Z Gemzar +Cisplatin + Avastin
) w7 L9 v- v" m+ p5 R, ^6 r5 fhttp://annonc.oxfordjournals.org/content/21/9/1804.full
7 d/ j' U; P3 [8 ~" hOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) # K2 q* v1 Q/ ]- T5 A- G4 J
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: `8 o* T0 X# p% J" U6 NResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( m1 J/ e v0 v% ^6 F4 D
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 199)
! K7 E% c+ M: m: a0 k华为网盘附件：; |8 v+ K2 l8 o# s6 p9 x
【华为网盘】ava.JPG
4 O. r' B& }* f8 n; x2 { |
显身卡
